Advancing Breakthrough, Targeted Cancer Therapies
Demonstrated proof-of-concept in Phase 0 IIT
Advancing Breakthrough, Targeted Cancer Therapies
Demonstrated proof-of-concept in Phase 0 IIT
About Zencogene
At Zencogene, we are committed to improving clinical outcomes for cancer patients. We utilize humanized antibodies that are highly specific to novel cancer targets.
Our Founder and CEO is Dr. Xinmin Zheng.
Dr. Zheng and et al were first to demonstrate that PTPRA could activate endogenous Src family kinases, and this induced cell transformation and tumourgenesis while at the the Institute of Molecular and Cell Biology of Singapore National University.
Thus, PTPRA was the first tyrosine phosphatase to be classified as a proto-oncoprotein.
Dr. Zheng also observed that PTPRA protein is overexpressed in certain human cancers, suggesting PTPRA should be considered a specific target for the advancement of next generation targeted therapies.
Our approach combines Dr. Xinmin Zheng's ability to design and engineer highly specific antibodies targeting emerging cancer targets that are critical to cancer metastasis, with the executional speed and cost efficiency of a Chinese biotech.